Represent Uranium Resources, Inc. in its acquisition of ASX-listed Anatolia Energy Limited.
David Crandall is a skilled advisor who works closely with clients to produce creative and efficient solutions in corporate and securities matters. David regularly advises companies regarding debt and equity financing in both public and private offerings, buying and selling public companies, shareholder and board matters, and public company obligations. David serves as outside general counsel to numerous companies in the mining, technology, and biopharma industries.
Years of representing a broad range of clients, from pre-revenue companies considering IPOs, to established Fortune 500 companies, have provided David a depth of knowledge to draw upon in meeting his clients' needs. His vast background of corporate and securities law allows him to provide timely and accurate advice.
David has represented issuers and underwriters in dozens of offerings amounting to billions of dollars. While he regularly represents large public companies in sizable underwritten debt and equity financings, he is also experienced in helping smaller clients meet their capital needs through mechanisms such as at-the-market offerings, registered direct offerings, and private equity lines.
David regularly represents companies in public mergers and acquisitions, both nationally and internationally, including tender offers and registered one-step mergers. He also counsels clients in defending against hostile take-overs.
For general corporate and public company obligations, David serves as an informed resource for clients, bringing years of experience in working with the Securities and Exchange Commission, shareholders, and boards of directors.
Represent Regal Entertainment Group in several bond offerings for over aB dollars and tender offers and redemptions of existing bonds.
Represent Ciena Corporation in its approximately US$400m acquisition of Cyan Inc.
Represent Royal Gold, Inc. in over US$800m of common stock and convertible debt offerings.
Represent numerous issuers in establishing at-the-market and private equity line agreements.
Represent a Canadian company in its acquisition of a public U.S. computer software company.
Represent Array BioPharma and TESARO, Inc. in convertible debt offerings in excess of US$300m.
Represent Cellceutix Corporation in establishing public company governance matters and holding first ever annual meeting of shareholders.